Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $231,325.71 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 32,263 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $7.17, for a total value of $231,325.71. Following the transaction, the insider directly owned 4,144,952 shares in the company, valued at approximately $29,719,305.84. This represents a 0.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $7.13 on Friday. Entrada Therapeutics, Inc. has a one year low of $5.02 and a one year high of $16.45. The company has a market cap of $277.62 million, a P/E ratio of -1.80 and a beta of -0.25. The firm has a fifty day moving average of $7.06 and a two-hundred day moving average of $9.19.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. As a group, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Roth Capital restated a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Institutional Trading of Entrada Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares in the last quarter. Rhumbline Advisers grew its stake in Entrada Therapeutics by 8.3% during the 2nd quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock valued at $263,000 after purchasing an additional 2,982 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Entrada Therapeutics by 10.8% in the second quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after buying an additional 7,301 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Entrada Therapeutics by 23.4% in the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after purchasing an additional 5,370 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Entrada Therapeutics by 34.2% during the second quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock valued at $150,000 after buying an additional 5,702 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.